Last reviewed · How we verify
NCT05016050
Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)
NA trial testing HPDT-DA-013 in Major Depressive Disorder in 367 participants. Completed in 14 April 2023.
16 March 2023
Quick facts
| Lead sponsor | Happify Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 367 |
| Start date | 9 August 2021 |
| Primary completion | 16 March 2023 |
| Estimated completion | 14 April 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- HPDT-DA-013
Conditions studied
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
- Generalized Anxiety Disorder — all drugs for Generalized Anxiety Disorder →
Sponsor
Happify Inc.
Who can join
22 and older, any sex, with Major Depressive Disorder or Generalized Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time. After the treatment period, participants will be followed monthly for 12 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05016050
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Major Depressive Disorder
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting
Other Happify Inc. trials
Trials by the same sponsor.
- NCT04567888 — Testing a Digital Intervention for Adolescents · NA · completed
- NCT04068805 — Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II) · NA · terminated
- NCT04112225 — Testing the Effectiveness of an Online Behavioral Intervention in Reducing Loneliness · NA · completed
- NCT03306654 — Efficacy of Three Online Well-Being Programs to Improve Work-Related Outcomes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05016050 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Happify Inc.
- Last refreshed: 1 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05016050.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing